Could 7 days of antifungals be enough for kids with blood infections?
NCT ID NCT05763251
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares a 7-day course of antifungal therapy to the standard 14-day course for children with uncomplicated candidemia (a blood infection caused by Candida fungus). About 420 children who have already received 7 days of treatment will be randomly assigned to stop or continue for another week. The goal is to see if the shorter treatment is just as effective, which could mean fewer side effects and less time in the hospital.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- antifungal therapy (echinocandin)
- What this could lead to
- If successful, this could show that a shorter course of antifungal treatment is just as effective as the standard longer course for children with uncomplicated candidemia, potentially reducing side effects and hospital stays.
- What could go wrong
- This is a phase 2/3 trial, so results are not yet proven. The shorter course might not be as effective, leading to higher relapse rates. The study also uses a biomarker test that may not be perfectly accurate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 420 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2023
- Expected to finish
-
Jun 2032
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
120 days and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age \> 120 days at the time of the first negative blood culture at any participating site; 2. Candidemia with at least one positive blood culture for any Candida spp; 3. Receiving/received an echinocandin (caspofungin, micafungin, anidulafungin, or rezafungin) as primary antifungal therapy for candidemia for at least 2 days from day of first negative culture with continuation of uninterrupted systemic antifungal therapy at the time of enrollment); 4. Sustained clearance of Candida spp. defined as negative blood culture(s) obtained after onset of candidemia and before day of randomization; 5. Partial or complete clinical response, as defined by published guidelines (Table 5), on or before day of randomization; 6. Between the onset of qualifying candidemia and randomization, no suspicion of disseminated candidiasis by patient's clinical team or, if deemed clinically necessary, documented negative radiological imaging such as an abdominal ultrasound or abdominal CT scan. Exclusion Criteria: 1. Already receiving antifungal therapy for a previously diagnosed systemic invasive fungal disease; 2. Neutropenic (absolute neutrophil count \< 500 cells/µl) at the time of enrollment or anticipated to be neutropenic in the week following randomization; 3. Have an underlying condition that requires them to be on antifungal prophylaxis when not receiving directed therapy for an invasive fungal disease; 4. Previous enrollment in this trial; 5. Females of childbearing age with a current pregnancy diagnosis or without a negative pregnancy test for their current admission; 6. A documented DNR order; 7. Have an implantable cardiac device (e.g., ventricular assist device, pacemaker)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Candidemia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
22 sites in 2 countries. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Arkansas Children's Hospital
RECRUITINGLittle Rock, Arkansas, 72202, United States
-
Boston Children's Hospital
RECRUITINGBoston, Massachusetts, 02115, United States
-
CS Mott Children's Hospital
RECRUITINGAnn Arbor, Michigan, 48109, United States
-
Children's Healthcare of Atlanta
RECRUITINGAtlanta, Georgia, 31193, United States
-
Children's Hospital of Alabama
RECRUITINGBirmingham, Alabama, 35233, United States
-
Children's Hospital of Orange County
RECRUITINGOrange, California, 92868, United States
-
Children's Hospital of Philadelphia
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
-
Children's Hospital of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
-
Cincinnati Children's Hospital
RECRUITINGCincinnati, Ohio, 45229, United States
-
Comer Children's Hospital
RECRUITINGChicago, Illinois, 60637, United States
-
Dell Children's Medical Center
RECRUITINGAustin, Texas, 78723, United States
-
Duke Children's Hospital
RECRUITINGDurham, North Carolina, 27705, United States
-
Lurie Children's Hospital of Chicago
RECRUITINGChicago, Illinois, 60611, United States
-
Nationwide Children's Hospital
RECRUITINGColumbus, Ohio, 43205, United States
-
Perth Children's Hospital
RECRUITINGPerth, Western Australia, 6009, Australia
-
Primary Children's Hospital
RECRUITINGSalt Lake City, Utah, 84113, United States
-
Riley Children's Hospital
RECRUITINGIndianapolis, Indiana, 46202, United States
-
University of Nebraska Medical Center
RECRUITINGOmaha, Nebraska, 68198, United States
-
University of Texas Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
-
Washington University St. Louis
RECRUITINGSt Louis, Missouri, 63130, United States
-
Weill Cornell Medical College
RECRUITINGNew York, New York, 10065, United States
-
Yale New Haven Children's Hospital
RECRUITINGNew Haven, Connecticut, 06510, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Once-a-Week IV antifungal tested against daily standard for dangerous candida infections
- Can a 10-Day antifungal course beat the standard 14 days?
- Can a quick PCR test speed up lifesaving fungal infection diagnosis?
- Blood biomarkers may let ICU patients stop antifungals earlier
- Immune booster shows promise in fighting dangerous fungal infection
- Candida resistance study pulled before it began